51
|
Wu N, Zhang H, Deng F, Li R, Zhang W, Chen X, Wen S, Wang N, Zhang J, Yin L, Liao Z, Zhang Z, Zhang Q, Yan Z, Liu W, Wu D, Ye J, Deng Y, Yang K, Luu HH, Haydon RC, He TC. Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in HEK-293 packaging cells. Gene Ther 2014; 21:629-37. [PMID: 24784448 DOI: 10.1038/gt.2014.40] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Revised: 03/13/2014] [Accepted: 03/21/2014] [Indexed: 12/29/2022]
Abstract
Recombinant adenoviruses are one of the most common vehicles for efficient in vitro and in vivo gene deliveries. Here, we investigate whether exogenous precursor terminal protein (pTP) expression in 293 cells improves the efficiency of adenovirus packaging and amplification. We used a piggyBac transposon-based vector and engineered a stable 293 line that expresses high level of Ad5 pTP, designated as 293pTP. Using the AdBMP6-GLuc that expresses green fluorescent protein (GFP), BMP6 and Gaussia luciferase, we found that the infectivity of AdBMP6-GLuc viral samples packaged in 293pTP cells was titrated up to 19.3 times higher than that packaged in parental 293 cells. AdBMP6-GLuc viral samples packaged in 293pTP cells exhibited significantly higher transduction efficiency in 143B and immortalized mouse embryonic fibroblast (iMEF) cells, as assessed by fluorescence-activated cell sorting analysis of GFP-positive cells, the luciferase activity assay and BMP6-induced osteogenic marker alkaline phosphatase activities in iMEFs. When adenovirus amplification efficiency was analyzed, we found that 293pTP cells infected with AdBMP6-GLuc yielded up to 12.6 times higher titer than that in parental 293 cells, especially at lower multiplicities of infection. These results strongly suggest that exogenous pTP expression may accelerate the packaging and amplification of recombinant adenoviruses. Thus, the engineered 293pTP cells should be a superior packaging line for efficient adenovirus production.
Collapse
|
52
|
Xiao Y, Jiang M, Luo Z, Zhou Y, Wen S, Wang M, Zhang C, Liu S. Identification and analysis of the jnk1 gene in polyploid hybrids of red crucian carp (Carassius auratus red var.) and common carp (Cyprinus carpio L.). GENETICS AND MOLECULAR RESEARCH 2014; 13:906-19. [DOI: 10.4238/2014.february.19.1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
53
|
Jiang B, Deng Y, Taha M, Wen S, Courtman D, Stewart D. Strain-Specific Differences in the Response to Inhibition of VEGFR2 in the SU5416 Model of Severe Plexogenic Pulmonary Arterial Hypertension. Can J Cardiol 2013. [DOI: 10.1016/j.cjca.2013.07.509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
54
|
Wang Z, Wen S, Zhang Q, Liu G, Wu X, Cong W. Power Consumption of Liquid and Liquid/Solid Systems in a Rotating-Drum Bioreactor. Chem Eng Technol 2013. [DOI: 10.1002/ceat.201200523] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
55
|
Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol 2013; 24:2158-65. [PMID: 23576709 DOI: 10.1093/annonc/mdt115] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The purpose of the study was to assess the outcome of patients with advanced melanoma treated with matched molecularly targeted therapy. PATIENTS AND METHODS We reviewed 160 consecutive patients with metastatic melanoma treated in the phase I program (N = 35 protocols). Treatment was considered to be 'matched' (N = 84) if at least one drug in the regimen was known to inhibit the functional activity of at least one of the patient's mutations. RESULTS Of 160 patients, 134 (83.7%) had adequate tissue for molecular analysis; 69% (110 of 160) had ≥1 mutation: 61.2% (82 of 134), BRAF; 20.7% (23 of 111), NRAS; 2.6% (2 of 77), KIT; 2.3% (1 of 44), KRAS; 20% (1 of 5), GNAQ; 11.1% (1 of 9), P53 and 2.6% (1 of 39), coexisting mutations in BRAF and PIK3CA. Eighty-four patients (52.4%) were treated with matched-targeted agents, most of whom had BRAF mutations (N = 74). Twenty-six percent of patients (41 of 160) achieved a complete or partial remission (CR/PR) [40% (34 of 84)) on a matched phase I protocol versus 9.2% (7 of 76) for those on a non-matched study (P ≤ 0.0001)]. The median progression-free survival (PFS) (95% CI) was longer for patients treated on a matched phase I trial than on their prior first standard treatment [5.27 (4.10, 6.44) versus 3.10 (1.92, 4.28) months, P = 0.023], but not on non-matched phase I treatment. Multivariable analysis showed that matched therapy was an independent predictor of higher CR/PR rates, prolonged PFS and survival. CONCLUSIONS For melanoma patients, especially those with BRAF mutations, administering molecularly matched agents can be associated with better outcomes, including longer PFS compared with their first-line systemic therapy.
Collapse
|
56
|
Bai R, Zhao P, Cao G, Wen S, Li Q, Meng Q. Ghrelin promotion of oocyte maturation via ERK1/2 pathway in ovis aries. Cell Mol Biol (Noisy-le-grand) 2012; 58 Suppl:OL1797-OL1802. [PMID: 23217439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2012] [Accepted: 11/23/2012] [Indexed: 06/01/2023]
Abstract
Ghrelin has recently garnered increasing attention in biomolecular studies. Ghrelin's growth hormone secretagogue receptor type 1a (GHS--R) is a pleiotropic modulator of diverse biological functions, including energy homeostasis and reproduction. This study sought to understand the ways in which ghrelin impacts ERK1/2 and p90rsk during the ovis aries oocyte maturation process. We applied different concentrations of ghrelin and of ghrelin receptor inhibitor (D--Lys3--GHRP--6) to ovis aries oocytes and observed the effects on the ERK1/2 and p90rsk pathway. The ERK1/2 and p90rsk pathway plays an essential role in the in vitro maturation of ovis aries oocytes. This study discovered that ERK1/2 and p90 rsk pathway, during the ovis aries oocyte maturation, was associated with maturation of ovis aries oocyte in vitro.
Collapse
|
57
|
Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 2012; 23:2960-2963. [PMID: 22745218 PMCID: PMC4092255 DOI: 10.1093/annonc/mds130] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2012] [Accepted: 03/27/2012] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Cardiac sequelae from oncologic drugs are important in early cancer drug development. Prolongation of the corrected QT interval (QTc) by noncardiac drugs is the most common cause of drug development delays, nonapprovals and postmarketing withdrawals by the US Food and Drug Administration. PATIENTS AND METHODS We analyzed 8518 electrocardiograms (ECGs) in 525 consecutive cancer patients enrolled in 22 industry-sponsored phase I clinical trials, starting 1 January 2006. RESULTS Seventy-four patients [14%, 95% confidence interval (CI) 11% to 17%] with normal QTc at baseline had QTc intervals above upper limit of normal after treatment initiation; 33 (6%, 95% CI 4% to 9%) had prolonged QTc intervals at baseline, and only one (3%, 95% CI 0% to 16%) worsened after dosing. Seven of 33 patients (21%, 95% CI 9% to 39%) with prolonged baseline QTc had normalization of QTc intervals after dosing. All QTc prolongations were clinically insignificant; study drugs were continued uneventfully. Two of 525 patients (0.4%, 95% CI 0% to 1%) experienced cardiac serious adverse events (myocardial infarction possibly related to drug and unstable atrial flutter related to metastatic disease). Both cardiac events were detected by clinical assessment, not surveillance ECGs. CONCLUSION Frequent ECG monitoring provided no clinically significant information in 525 patients in early phase trials.
Collapse
|
58
|
Kurzrock R, Tsimberidou A, Hong D, Wheler J, Falchook G, Fu S, Naing A, Janku F, Wen S, Berry D. 18 Pursuing Molecular Stratification in Phase I Trials. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71817-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
59
|
Wen S, Tsuji T, Li X, Mimura Y, Sasaki K, Shinozaki F. Immunohistochemical detection of p53 protein and proliferating cell nuclear antigen (pcna) in salivary-gland tumors. Oncol Rep 2012; 2:233-6. [PMID: 21597718 DOI: 10.3892/or.2.2.233] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The expression of p53 protein and PCNA was immunohistochemically examined in 161 cases of salivary gland tumors. The p53 protein was positive in 23.8% (24/101) of malignant salivary gland tumors, while only one case of 60 pleomorphic adenomas was positive. p53 protein was frequently detectable in salivary duct carcinoma (60%), basal cell adenocarcinoma (66.7%), acinic cell carcinoma (53.3%) and undifferentiated carcinoma (50%), but was rarely seen in adenoid cystic carcinoma (17.2%) and mucoepidermoid carcinoma (0%). p53 protein was more frequently detectable in PCNA positive cases than in negative cases (p=0.0074).
Collapse
|
60
|
Zhang Q, Wang Z, Wen S, Liu G, Wu X, Cong W. Gas-Liquid Mass Transfer Characteristics in a Rotating-Drum Bioreactor. Chem Eng Technol 2012. [DOI: 10.1002/ceat.201200172] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
61
|
Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol 2012; 23:1963-1967. [PMID: 22377564 PMCID: PMC4092254 DOI: 10.1093/annonc/mds027] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2011] [Revised: 12/20/2011] [Accepted: 01/20/2012] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND This study assessed toxicity in advanced cancer patients treated in a phase I clinic that focuses on targeted agents. PATIENTS AND METHODS An analysis of database records of 1181 consecutive patients with advanced cancer who were treated in the phase I program starting 1 January 2006 was carried out. RESULTS All patients were treated on at least 1 of the 82 phase I clinical trials. Overall, 56 trials (68.3%) had only targeted agents, 13 (15.9%) only cytotoxics, and 13 (15.9%) targeted and cytotoxic agents. Rates of grade 3 and 4 toxicity that were at least possibly drug related were 7.1% and 3.2%, respectively, and 5 of the 1181 patients (0.4%) died from toxicity that was at least possibly drug related. The most common grade 3 or more toxic effects were neutropenia, thrombocytopenia, anemia, dehydration, infection, altered mental status, bleeding, vomiting, nausea, and diarrhea. Eastern Cooperative Oncology Group (ECOG) performance status greater than zero and use of a cytotoxic agent were selected as independent factors associated with serious toxicity. CONCLUSION Phase I trials of primarily targeted agents showed low rates of toxicity, with 10.3% of patients experiencing grade 3 or 4 toxicity and a 0.4% rate of death, at least possibly drug related.
Collapse
|
62
|
Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia 2012; 26:2428-31. [PMID: 22665218 DOI: 10.1038/leu.2012.153] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
63
|
Doroshow J, Liu ET, Pellini M, Miller V, Palmer G, Averbuch S, Green G, Novotny J, Paoletti P, Patel K, Hoos A, Gaynor R, Melemed S, Reinhard C, Teh BT, Hong WK, Kim E, Herbst R, Papadimitrakopoulou V, Gold K, Wistuba I, Lee J, Lippman S, Jackson JR, Zitvogel L, Meisel C, Workman P, Dalton WS, Botwood N, Davis BJ, Batist G, Assouline S, Camlioglu E, Tetu B, Spatz A, Diaz Z, Aguilar-Mahecha A, Basik M, Rodon J, Dienstmann R, Cortes J, Saura C, Aura C, Hernandez-Losa J, Vivancos A, Joan J, del Campo J, Felip E, Seoane J, Tabernero JT, Friend SH, Tsimberidou AM, Hong DS, Wheler JJ, Ye Y, Fu S, Piha-Paul SA, Naing A, Falchook GS, Janku F, Luthra R, Wen S, Kurzrock R, Naley M, Johnson P, Schuerer K, Lopes M, Hood LE, Yarden Y, Quackenbush J. Lectures. Ann Oncol 2012. [DOI: 10.1093/annonc/mds160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
64
|
Abadie J, Abbott BP, Abbott R, Adhikari R, Ajith P, Allen B, Allen G, Amador Ceron E, Amin RS, Anderson SB, Anderson WG, Arain MA, Araya M, Aso Y, Aston S, Aufmuth P, Aulbert C, Babak S, Baker P, Ballmer S, Barker D, Barr B, Barriga P, Barsotti L, Barton MA, Bartos I, Bassiri R, Bastarrika M, Behnke B, Benacquista M, Bennett MF, Betzwieser J, Beyersdorf PT, Bilenko IA, Billingsley G, Biswas R, Black E, Blackburn JK, Blackburn L, Blair D, Bland B, Bock O, Bodiya TP, Bondarescu R, Bork R, Born M, Bose S, Brady PR, Braginsky VB, Brau JE, Breyer J, Bridges DO, Brinkmann M, Britzger M, Brooks AF, Brown DA, Bullington A, Buonanno A, Burmeister O, Byer RL, Cadonati L, Cain J, Camp JB, Cannizzo J, Cannon KC, Cao J, Capano C, Cardenas L, Caudill S, Cavaglià M, Cepeda C, Chalermsongsak T, Chalkley E, Charlton P, Chatterji S, Chelkowski S, Chen Y, Christensen N, Chua SSY, Chung CTY, Clark D, Clark J, Clayton JH, Conte R, Cook D, Corbitt TRC, Cornish N, Coward D, Coyne DC, Creighton JDE, Creighton TD, Cruise AM, Culter RM, Cumming A, Cunningham L, Dahl K, Danilishin SL, Danzmann K, Daudert B, Davies G, Daw EJ, Dayanga T, DeBra D, Degallaix J, Dergachev V, DeSalvo R, Dhurandhar S, Díaz M, Donovan F, Dooley KL, Doomes EE, Drever RWP, Driggers J, Dueck J, Duke I, Dumas JC, Dwyer S, Edgar M, Edwards M, Effler A, Ehrens P, Etzel T, Evans M, Evans T, Fairhurst S, Faltas Y, Fan Y, Fazi D, Fehrmann H, Finn LS, Flasch K, Foley S, Forrest C, Fotopoulos N, Frede M, Frei M, Frei Z, Freise A, Frey R, Fricke TT, Friedrich D, Fritschel P, Frolov VV, Fulda P, Fyffe M, Garofoli JA, Ghosh S, Giaime JA, Giampanis S, Giardina KD, Goetz E, Goggin LM, González G, Goßler S, Grant A, Gras S, Gray C, Greenhalgh RJS, Gretarsson AM, Grosso R, Grote H, Grunewald S, Gustafson EK, Gustafson R, Hage B, Hallam JM, Hammer D, Hammond GD, Hanna C, Hanson J, Harms J, Harry GM, Harry IW, Harstad ED, Haughian K, Hayama K, Hayler T, Heefner J, Heng IS, Heptonstall A, Hewitson M, Hild S, Hirose E, Hoak D, Hodge KA, Holt K, Hosken DJ, Hough J, Howell E, Hoyland D, Hughey B, Husa S, Huttner SH, Ingram DR, Isogai T, Ivanov A, Johnson WW, Jones DI, Jones G, Jones R, Ju L, Kalmus P, Kalogera V, Kandhasamy S, Kanner J, Katsavounidis E, Kawabe K, Kawamura S, Kawazoe F, Kells W, Keppel DG, Khalaidovski A, Khalili FY, Khan R, Khazanov E, Kim H, King PJ, Kissel JS, Klimenko S, Kokeyama K, Kondrashov V, Kopparapu R, Koranda S, Kozak D, Kringel V, Krishnan B, Kuehn G, Kullman J, Kumar R, Kwee P, Lam PK, Landry M, Lang M, Lantz B, Lastzka N, Lazzarini A, Leaci P, Lei M, Leindecker N, Leonor I, Lin H, Lindquist PE, Littenberg TB, Lockerbie NA, Lodhia D, Lormand M, Lu P, Lubinski M, Lucianetti A, Lück H, Lundgren A, Machenschalk B, MacInnis M, Mageswaran M, Mailand K, Mak C, Mandel I, Mandic V, Márka S, Márka Z, Markosyan A, Markowitz J, Maros E, Martin IW, Martin RM, Marx JN, Mason K, Matichard F, Matone L, Matzner RA, Mavalvala N, McCarthy R, McClelland DE, McGuire SC, McIntyre G, McKechan DJA, Mehmet M, Melatos A, Melissinos AC, Mendell G, Menéndez DF, Mercer RA, Merrill L, Meshkov S, Messenger C, Meyer MS, Miao H, Miller J, Mino Y, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Miyakawa O, Moe B, Mohanty SD, Mohapatra SRP, Moreno G, Mors K, Mossavi K, MowLowry C, Mueller G, Müller-Ebhardt H, Mukherjee S, Mullavey A, Munch J, Murray PG, Nash T, Nawrodt R, Nelson J, Newton G, Nishida E, Nishizawa A, O’Dell J, O’Reilly B, O’Shaughnessy R, Ochsner E, Ogin GH, Oldenburg R, Ottaway DJ, Ottens RS, Overmier H, Owen BJ, Page A, Pan Y, Pankow C, Papa MA, Patel P, Pathak D, Pedraza M, Pekowsky L, Penn S, Peralta C, Perreca A, Pickenpack M, Pinto IM, Pitkin M, Pletsch HJ, Plissi MV, Postiglione F, Principe M, Prix R, Prokhorov L, Puncken O, Quetschke V, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raics Z, Rakhmanov M, Raymond V, Reed CM, Reed T, Rehbein H, Reid S, Reitze DH, Riesen R, Riles K, Roberts P, Robertson NA, Robinson C, Robinson EL, Roddy S, Röver C, Rollins J, Romano JD, Romie JH, Rowan S, Rüdiger A, Ryan K, Sakata S, Sammut L, Sancho de la Jordana L, Sandberg V, Sannibale V, Santamaría L, Santostasi G, Saraf S, Sarin P, Sathyaprakash BS, Sato S, Satterthwaite M, Saulson PR, Savage R, Schilling R, Schnabel R, Schofield R, Schulz B, Schutz BF, Schwinberg P, Scott J, Scott SM, Searle AC, Seifert F, Sellers D, Sengupta AS, Sergeev A, Shapiro B, Shawhan P, Shoemaker DH, Sibley A, Siemens X, Sigg D, Sintes AM, Skelton G, Slagmolen BJJ, Slutsky J, Smith JR, Smith MR, Smith ND, Somiya K, Sorazu B, Speirits F, Stein AJ, Stein LC, Steplewski S, Stochino A, Stone R, Strain KA, Strigin S, Stroeer A, Stuver AL, Summerscales TZ, Sung M, Susmithan S, Sutton PJ, Szokoly GP, Talukder D, Tanner DB, Tarabrin SP, Taylor JR, Taylor R, Thorne KA, Thorne KS, Thüring A, Titsler C, Tokmakov KV, Torres C, Torrie CI, Traylor G, Trias M, Turner L, Ugolini D, Urbanek K, Vahlbruch H, Vallisneri M, Van Den Broeck C, van der Sluys MV, van Veggel AA, Vass S, Vaulin R, Vecchio A, Veitch J, Veitch PJ, Veltkamp C, Villar A, Vorvick C, Vyachanin SP, Waldman SJ, Wallace L, Wanner A, Ward RL, Wei P, Weinert M, Weinstein AJ, Weiss R, Wen L, Wen S, Wessels P, West M, Westphal T, Wette K, Whelan JT, Whitcomb SE, Whiting BF, Wilkinson C, Willems PA, Williams HR, Williams L, Willke B, Wilmut I, Winkelmann L, Winkler W, Wipf CC, Wiseman AG, Woan G, Wooley R, Worden J, Yakushin I, Yamamoto H, Yamamoto K, Yeaton-Massey D, Yoshida S, Zanolin M, Zhang L, Zhang Z, Zhao C, Zotov N, Zucker ME, Zweizig J, Buchner S. Publisher’s Note: Search for gravitational waves associated with the August 2006 timing glitch of the Vela pulsar [Phys. Rev. D83, 042001 (2011)]. Int J Clin Exp Med 2012. [DOI: 10.1103/physrevd.85.089902] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
65
|
Abadie J, Abbott BP, Abbott R, Abernathy M, Accadia T, Acernese F, Adams C, Adhikari R, Ajith P, Allen B, Allen G, Amador Ceron E, Amin RS, Anderson SB, Anderson WG, Antonucci F, Arain MA, Araya M, Aronsson M, Arun KG, Aso Y, Aston S, Astone P, Atkinson DE, Aufmuth P, Aulbert C, Babak S, Baker P, Ballardin G, Ballinger T, Ballmer S, Barker D, Barnum S, Barone F, Barr B, Barriga P, Barsotti L, Barsuglia M, Barton MA, Bartos I, Bassiri R, Bastarrika M, Bauchrowitz J, Bauer TS, Behnke B, Beker MG, Belletoile A, Benacquista M, Bertolini A, Betzwieser J, Beveridge N, Beyersdorf PT, Bigotta S, Bilenko IA, Billingsley G, Birch J, Birindelli S, Biswas R, Bitossi M, Bizouard MA, Black E, Blackburn JK, Blackburn L, Blair D, Bland B, Blom M, Boccara C, Bock O, Bodiya TP, Bondarescu R, Bondu F, Bonelli L, Bonnand R, Bork R, Born M, Bose S, Bosi L, Bouhou B, Boyle M, Braccini S, Bradaschia C, Brady PR, Braginsky VB, Brau JE, Breyer J, Bridges DO, Brillet A, Brinkmann M, Brisson V, Britzger M, Brooks AF, Brown DA, Budzyński R, Bulik T, Bulten HJ, Buonanno A, Burguet-Castell J, Burmeister O, Buskulic D, Buy C, Byer RL, Cadonati L, Cagnoli G, Cain J, Calloni E, Camp JB, Campagna E, Campsie P, Cannizzo J, Cannon KC, Canuel B, Cao J, Capano C, Carbognani F, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda C, Cesarini E, Chalermsongsak T, Chalkley E, Charlton P, Chassande-Mottin E, Chelkowski S, Chen Y, Chincarini A, Christensen N, Chua SSY, Chung CTY, Clark D, Clark J, Clayton JH, Cleva F, Coccia E, Colacino CN, Colas J, Colla A, Colombini M, Conte R, Cook D, Corbitt TR, Cornish N, Corsi A, Costa CA, Coulon JP, Coward D, Coyne DC, Creighton JDE, Creighton TD, Cruise AM, Culter RM, Cumming A, Cunningham L, Cuoco E, Dahl K, Danilishin SL, Dannenberg R, D’Antonio S, Danzmann K, Das K, Dattilo V, Daudert B, Davier M, Davies G, Davis A, Daw EJ, Day R, Dayanga T, De Rosa R, DeBra D, Degallaix J, del Prete M, Dergachev V, DeRosa R, DeSalvo R, Devanka P, Dhurandhar S, Di Fiore L, Di Lieto A, Di Palma I, Di Paolo Emilio M, Di Virgilio A, Díaz M, Dietz A, Donovan F, Dooley KL, Doomes EE, Dorsher S, Douglas ESD, Drago M, Drever RWP, Driggers JC, Dueck J, Dumas JC, Dwyer S, Eberle T, Edgar M, Edwards M, Effler A, Ehrens P, Ely G, Engel R, Etzel T, Evans M, Evans T, Fafone V, Fairhurst S, Fan Y, Farr BF, Fazi D, Fehrmann H, Feldbaum D, Ferrante I, Fidecaro F, Finn LS, Fiori I, Flaminio R, Flanigan M, Flasch K, Foley S, Forrest C, Forsi E, Fotopoulos N, Fournier JD, Franc J, Frasca S, Frasconi F, Frede M, Frei M, Frei Z, Freise A, Frey R, Fricke TT, Friedrich D, Fritschel P, Frolov VV, Fulda P, Fyffe M, Galimberti M, Gammaitoni L, Garofoli JA, Garufi F, Gemme G, Genin E, Gennai A, Ghosh S, Giaime JA, Giampanis S, Giardina KD, Giazotto A, Gill C, Goetz E, Goggin LM, González G, Goßler S, Gouaty R, Graef C, Granata M, Grant A, Gras S, Gray C, Greenhalgh RJS, Gretarsson AM, Greverie C, Grosso R, Grote H, Grunewald S, Guidi GM, Gustafson EK, Gustafson R, Hage B, Hall P, Hallam JM, Hammer D, Hammond G, Hanks J, Hanna C, Hanson J, Harms J, Harry GM, Harry IW, Harstad ED, Haughian K, Hayama K, Hayau JF, Hayler T, Heefner J, Heitmann H, Hello P, Heng IS, Heptonstall A, Hewitson M, Hild S, Hirose E, Hoak D, Hodge KA, Holt K, Hosken DJ, Hough J, Howell E, Hoyland D, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Ingram DR, Inta R, Isogai T, Ivanov A, Jaranowski P, Johnson WW, Jones DI, Jones G, Jones R, Ju L, Kalmus P, Kalogera V, Kandhasamy S, Kanner J, Katsavounidis E, Kawabe K, Kawamura S, Kawazoe F, Kells W, Keppel DG, Khalaidovski A, Khalili FY, Khazanov EA, Kim H, King PJ, Kinzel DL, Kissel JS, Klimenko S, Kondrashov V, Kopparapu R, Koranda S, Kowalska I, Kozak D, Krause T, Kringel V, Krishnamurthy S, Krishnan B, Królak A, Kuehn G, Kullman J, Kumar R, Kwee P, Landry M, Lang M, Lantz B, Lastzka N, Lazzarini A, Leaci P, Leong J, Leonor I, Leroy N, Letendre N, Li J, Li TGF, Lin H, Lindquist PE, Lockerbie NA, Lodhia D, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lu P, Luan J, Lubinski M, Lucianetti A, Lück H, Lundgren A, Machenschalk B, MacInnis M, Mageswaran M, Mailand K, Majorana E, Mak C, Maksimovic I, Man N, Mandel I, Mandic V, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Maros E, Marque J, Martelli F, Martin IW, Martin RM, Marx JN, Mason K, Masserot A, Matichard F, Matone L, Matzner RA, Mavalvala N, McCarthy R, McClelland DE, McGuire SC, McIntyre G, McIvor G, McKechan DJA, Meadors G, Mehmet M, Meier T, Melatos A, Melissinos AC, Mendell G, Menéndez DF, Mercer RA, Merill L, Meshkov S, Messenger C, Meyer MS, Miao H, Michel C, Milano L, Miller J, Minenkov Y, Mino Y, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moe B, Mohan M, Mohanty SD, Mohapatra SRP, Moraru D, Moreau J, Moreno G, Morgado N, Morgia A, Mors K, Mosca S, Moscatelli V, Mossavi K, Mours B, MowLowry C, Mueller G, Mukherjee S, Mullavey A, Müller-Ebhardt H, Munch J, Murray PG, Nash T, Nawrodt R, Nelson J, Neri I, Newton G, Nishida E, Nishizawa A, Nocera F, Nolting D, Ochsner E, O’Dell J, Ogin GH, Oldenburg RG, O’Reilly B, O’Shaughnessy R, Osthelder C, Ottaway DJ, Ottens RS, Overmier H, Owen BJ, Page A, Pagliaroli G, Palladino L, Palomba C, Pan Y, Pankow C, Paoletti F, Papa MA, Pardi S, Pareja M, Parisi M, Pasqualetti A, Passaquieti R, Passuello D, Patel P, Pathak D, Pedraza M, Pekowsky L, Penn S, Peralta C, Perreca A, Persichetti G, Pichot M, Pickenpack M, Piergiovanni F, Pietka M, Pinard L, Pinto IM, Pitkin M, Pletsch HJ, Plissi MV, Poggiani R, Postiglione F, Prato M, Predoi V, Price LR, Prijatelj M, Principe M, Prix R, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Quetschke V, Raab FJ, Rabeling DS, Radke T, Radkins H, Raffai P, Rakhmanov M, Rankins B, Rapagnani P, Raymond V, Re V, Reed CM, Reed T, Regimbau T, Reid S, Reitze DH, Ricci F, Riesen R, Riles K, Roberts P, Robertson NA, Robinet F, Robinson C, Robinson EL, Rocchi A, Roddy S, Röver C, Rolland L, Rollins J, Romano JD, Romano R, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Sakata S, Sakosky M, Salemi F, Sammut L, Sancho de la Jordana L, Sandberg V, Sannibale V, Santamaría L, Santostasi G, Saraf S, Sassolas B, Sathyaprakash BS, Sato S, Satterthwaite M, Saulson PR, Savage R, Schilling R, Schnabel R, Schofield R, Schulz B, Schutz BF, Schwinberg P, Scott J, Scott SM, Searle AC, Seifert F, Sellers D, Sengupta AS, Sentenac D, Sergeev A, Shaddock D, Shapiro B, Shawhan P, Shoemaker DH, Sibley A, Siemens X, Sigg D, Singer A, Sintes AM, Skelton G, Slagmolen BJJ, Slutsky J, Smith JR, Smith MR, Smith ND, Somiya K, Sorazu B, Speirits FC, Sperandio L, Stein AJ, Stein LC, Steinlechner S, Steplewski S, Stochino A, Stone R, Strain KA, Strigin S, Stroeer A, Sturani R, Stuver AL, Summerscales TZ, Sung M, Susmithan S, Sutton PJ, Swinkels B, Talukder D, Tanner DB, Tarabrin SP, Taylor JR, Taylor R, Thomas P, Thorne KA, Thorne KS, Thrane E, Thüring A, Titsler C, Tokmakov KV, Toncelli A, Tonelli M, Torre O, Torres C, Torrie CI, Tournefier E, Travasso F, Traylor G, Trias M, Trummer J, Tseng K, Turner L, Ugolini D, Urbanek K, Vahlbruch H, Vaishnav B, Vajente G, Vallisneri M, van den Brand JFJ, Van Den Broeck C, van der Putten S, van der Sluys MV, van Veggel AA, Vass S, Vaulin R, Vavoulidis M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Veltkamp C, Verkindt D, Vetrano F, Viceré A, Villar A, Vinet JY, Vocca H, Vorvick C, Vyachanin SP, Waldman SJ, Wallace L, Wanner A, Ward RL, Was M, Wei P, Weinert M, Weinstein AJ, Weiss R, Wen L, Wen S, Wessels P, West M, Westphal T, Wette K, Whelan JT, Whitcomb SE, White DJ, Whiting BF, Wilkinson C, Willems PA, Williams L, Willke B, Winkelmann L, Winkler W, Wipf CC, Wiseman AG, Woan G, Wooley R, Worden J, Yakushin I, Yamamoto H, Yamamoto K, Yeaton-Massey D, Yoshida S, Yu PP, Yvert M, Zanolin M, Zhang L, Zhang Z, Zhao C, Zotov N, Zucker ME, Zweizig J. Publisher’s Note: Search for gravitational waves from compact binary coalescence in LIGO and Virgo data from S5 and VSR1 [Phys. Rev. D82, 102001 (2010)]. Int J Clin Exp Med 2012. [DOI: 10.1103/physrevd.85.089903] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
66
|
Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, Eng C, Hassan MM. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 2012; 106:1374-8. [PMID: 22421948 PMCID: PMC3326682 DOI: 10.1038/bjc.2012.71] [Citation(s) in RCA: 118] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 02/14/2012] [Accepted: 02/17/2012] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Patients with type II diabetes mellitus (DM) have an increased risk of adenomatous colorectal (CRC) polyps and CRC cancer. The use of the anti-hyperglycemic agent metformin is associated with a reduced incidence of cancer-related deaths. METHODS We retrospectively evaluated the medical records of 4758 patients seen at a single institution and determined that 424 patients were identified by their physicians as having type II DM and CRC cancer. Data were subsequently acquired determining the subject's age, body mass index (BMI), and disease date of diagnosis, stage, site of cancer, treatment, and survival. RESULTS Patients with type II DM and CRC cancer treated with metformin as one of their diabetic medications had a survival of 76.9 months (95% CI=61.4-102.4) as compared with 56.9 months in those patients not treated with metformin (95% CI=44.8-68.8), P=0.048. By using a multivariable Cox regression model adjusted for age, sex, race, BMI, and initial stage of disease, we demonstrated that type II diabetic patients treated with metformin had a 30% improvement in overall survival (OS) when compared with diabetic patients treated with other diabetic agents. CONCLUSION Colorectal cancer patients with DM treated with metformin as part of their diabetic therapy appear to have a superior OS.
Collapse
|
67
|
Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol 2012; 22:2661-2666. [PMID: 22105611 DOI: 10.1093/annonc/mdr011] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Von Hippel-Lindau (VHL) disease induces vascular neoplasms in multiple organs. We evaluated the safety and efficacy of sunitinib in VHL patients and examined the expression of candidate receptors in archived tissue. METHODS Patients with VHL were given four cycles of 50 mg sunitinib daily for 28 days, followed by 14 days off. Primary end point was toxicity. Modified RECIST were used for efficacy assessment. We evaluated 20 archival renal cell carcinomas (RCCs) and 20 hemangioblastomas (HBs) for biomarker expression levels using laser-scanning cytometry (LSC). RESULTS Fifteen patients were treated. Grade 3 toxicity included fatigue in five patients. Dose reductions were needed in 10 patients. Eighteen RCC and 21 HB lesions were evaluable. Six of the RCCs (33%) responded partially, versus none of the HBs (P = 0.014). LSC revealed that mean levels of phosphorylated vascular endothelial growth factor receptor-2 were lower in HB than in RCC endothelium (P = 0.003) and mean phosphorylated fibroblast growth factor receptor substrate-2 (pFRS2) levels were higher in HB (P = 0.003). CONCLUSIONS Sunitinib treatment in VHL patients showed acceptable toxicity. Significant response was observed in RCC but not in HB. Greater expression of pFRS2 in HB tissue than in RCC raises the hypothesis that treatment with fibroblast growth factor pathway-blocking agents may benefit patients with HB.
Collapse
|
68
|
Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJ. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 2012; 23:652-658. [PMID: 21653683 PMCID: PMC3331734 DOI: 10.1093/annonc/mdr279] [Citation(s) in RCA: 77] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2011] [Revised: 04/06/2011] [Accepted: 04/07/2011] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Poorly differentiated and signet ring cell adenocarcinomas of the appendix represent a subset with aggressive tumor biology and poor outcomes with few studies evaluating the impact of systemic chemotherapy and cytoreductive surgery (CRS). PATIENTS AND METHODS A retrospective chart review of patients with either poorly differentiated and signet ring cell appendiceal adenocarcinomas was completed from 1992 to 2010. RESULTS One hundred forty-two patients were identified. Seventy-eight patients with metastatic disease received chemotherapy. Radiographic response was 44%, median progression-free survival (PFS) was 6.9 months, and median overall survival (OS) was 1.7 years. In multivariate analysis, response to chemotherapy [hazard ratio (HR) 0.5; P = 0.02] predicted improved PFS, and complete CRS (HR 0.3; P = 0.004) predicted improved OS. Patients who underwent complete CRS (n = 26) had a median relapse-free survival (RFS) of 1.2 years and a median OS of 4.2 years. In multivariate analysis for this subset, complete cytoreduction score of 0 was significantly correlated with improved RFS (HR 0.07; P = 0.01) and OS (HR 0.02; P = 0.01). CONCLUSIONS Systemic chemotherapy appears to be a viable treatment option for patients with metastatic poorly differentiated and signet ring cell appendiceal adenocarcinomas. Complete CRS is associated with improved RFS and OS, though part of this benefit likely reflects the selection of good tumor biology.
Collapse
|
69
|
Abadie J, Abbott BP, Abbott R, Abernathy M, Accadia T, Acernese F, Adams C, Adhikari R, Ajith P, Allen B, Allen GS, Ceron EA, Amin RS, Anderson SB, Anderson WG, Antonucci F, Arain MA, Araya MC, Aronsson M, Arun KG, Aso Y, Aston SM, Astone P, Atkinson D, Aufmuth P, Aulbert C, Babak S, Baker P, Ballardin G, Ballmer S, Barker D, Barnum S, Barone F, Barr B, Barriga P, Barsotti L, Barsuglia M, Barton MA, Bartos I, Bassiri R, Bastarrika M, Bauchrowitz J, Bauer TS, Behnke B, Beker MG, Belletoile A, Benacquista M, Bertolini A, Betzwieser J, Beveridge N, Beyersdorf PT, Bigotta S, Bilenko IA, Billingsley G, Birch J, Birindelli S, Biswas R, Bitossi M, Bizouard MA, Black E, Blackburn JK, Blackburn L, Blair D, Bland B, Blom M, Boccara C, Bock O, Bodiya TP, Bondarescu R, Bondu F, Bonelli L, Bonnand R, Bork R, Born M, Bose S, Bosi L, Bouhou B, Boyle M, Braccini S, Bradaschia C, Brady PR, Braginsky VB, Brau JE, Breyer J, Bridges DO, Brillet A, Brinkmann M, Brisson V, Britzger M, Brooks AF, Brown DA, Budzyński R, Bulik T, Bulten HJ, Buonanno A, Burguet-Castell J, Burmeister O, Buskulic D, Buy C, Byer RL, Cadonati L, Cagnoli G, Cain J, Calloni E, Camp JB, Campagna E, Campsie P, Cannizzo J, Cannon K, Canuel B, Cao J, Capano C, Carbognani F, Caride S, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda C, Cesarini E, Chalermsongsak T, Chalkley E, Charlton P, Chassande-Mottin E, Chelkowski S, Chen Y, Chincarini A, Christensen N, Chua SSY, Chung CTY, Clark D, Clark J, Clayton JH, Cleva F, Coccia E, Colacino CN, Colas J, Colla A, Colombini M, Conte R, Cook D, Corbitt TR, Cornish N, Corsi A, Costa CA, Coulon JP, Coward DM, Coyne DC, Creighton JDE, Creighton TD, Cruise AM, Culter RM, Cumming A, Cunningham L, Cuoco E, Dahl K, Danilishin SL, Dannenberg R, D'Antonio S, Danzmann K, Das K, Dattilo V, Daudert B, Davier M, Davies G, Davis A, Daw EJ, Day R, Dayanga T, De Rosa R, DeBra D, Degallaix J, del Prete M, Dergachev V, DeRosa R, DeSalvo R, Devanka P, Dhurandhar S, Di Fiore L, Di Lieto A, Di Palma I, Di Paolo Emilio M, Di Virgilio A, Díaz M, Dietz A, Donovan F, Dooley KL, Doomes EE, Dorsher S, Douglas ESD, Drago M, Drever RWP, Driggers JC, Dueck J, Dumas JC, Eberle T, Edgar M, Edwards M, Effler A, Ehrens P, Engel R, Etzel T, Evans M, Evans T, Fafone V, Fairhurst S, Fan Y, Farr BF, Fazi D, Fehrmann H, Feldbaum D, Ferrante I, Fidecaro F, Finn LS, Fiori I, Flaminio R, Flanigan M, Flasch K, Foley S, Forrest C, Forsi E, Fotopoulos N, Fournier JD, Franc J, Frasca S, Frasconi F, Frede M, Frei M, Frei Z, Freise A, Frey R, Fricke TT, Friedrich D, Fritschel P, Frolov VV, Fulda P, Fyffe M, Galimberti M, Gammaitoni L, Garofoli JA, Garufi F, Gemme G, Genin E, Gennai A, Gholami I, Ghosh S, Giaime JA, Giampanis S, Giardina KD, Giazotto A, Gill C, Goetz E, Goggin LM, González G, Gorodetsky ML, Gossler S, Gouaty R, Graef C, Granata M, Grant A, Gras S, Gray C, Greenhalgh RJS, Gretarsson AM, Greverie C, Grosso R, Grote H, Grunewald S, Guidi GM, Gustafson EK, Gustafson R, Hage B, Hall P, Hallam JM, Hammer D, Hammond G, Hanks J, Hanna C, Hanson J, Harms J, Harry GM, Harry IW, Harstad ED, Haughian K, Hayama K, Hayau JF, Hayler T, Heefner J, Heitmann H, Hello P, Heng IS, Heptonstall AW, Hewitson M, Hild S, Hirose E, Hoak D, Hodge KA, Holt K, Hosken DJ, Hough J, Howell EJ, Hoyland D, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Ingram DR, Inta R, Isogai T, Ivanov A, Jaranowski P, Johnson WW, Jones DI, Jones G, Jones R, Ju L, Kalmus P, Kalogera V, Kandhasamy S, Kanner JB, Katsavounidis E, Kawabe K, Kawamura S, Kawazoe F, Kells W, Keppel DG, Khalaidovski A, Khalili FY, Khazanov EA, Kim H, King PJ, Kinzel DL, Kissel JS, Klimenko S, Kondrashov V, Kopparapu R, Koranda S, Kowalska I, Kozak D, Krause T, Kringel V, Krishnamurthy S, Krishnan B, Królak A, Kuehn G, Kullman J, Kumar R, Kwee P, Landry M, Lang M, Lantz B, Lastzka N, Lazzarini A, Leaci P, Leong J, Leonor I, Leroy N, Letendre N, Li J, Li TGF, Liguori N, Lin H, Lindquist PE, Lockerbie NA, Lodhia D, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lu P, Luan J, Lubinski M, Lucianetti A, Lück H, Lundgren AD, Machenschalk B, MacInnis M, Mageswaran M, Mailand K, Majorana E, Mak C, Maksimovic I, Man N, Mandel I, Mandic V, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Maros E, Marque J, Martelli F, Martin IW, Martin RM, Marx JN, Mason K, Masserot A, Matichard F, Matone L, Matzner RA, Mavalvala N, McCarthy R, McClelland DE, McGuire SC, McIntyre G, McIvor G, McKechan DJA, Meadors G, Mehmet M, Meier T, Melatos A, Melissinos AC, Mendell G, Menéndez DF, Mercer RA, Merill L, Meshkov S, Messenger C, Meyer MS, Miao H, Michel C, Milano L, Miller J, Minenkov Y, Mino Y, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moe B, Mohan M, Mohanty SD, Mohapatra SRP, Moraru D, Moreau J, Moreno G, Morgado N, Morgia A, Morioka T, Mors K, Mosca S, Moscatelli V, Mossavi K, Mours B, Mow-Lowry CM, Mueller G, Mukherjee S, Mullavey A, Müller-Ebhardt H, Munch J, Murray PG, Nash T, Nawrodt R, Nelson J, Neri I, Newton G, Nishizawa A, Nocera F, Nolting D, Ochsner E, O'Dell J, Ogin GH, Oldenburg RG, O'Reilly B, O'Shaughnessy R, Osthelder C, Ottaway DJ, Ottens RS, Overmier H, Owen BJ, Page A, Pagliaroli G, Palladino L, Palomba C, Pan Y, Pankow C, Paoletti F, Papa MA, Pardi S, Pareja M, Parisi M, Pasqualetti A, Passaquieti R, Passuello D, Patel P, Pathak D, Pedraza M, Pekowsky L, Penn S, Peralta C, Perreca A, Persichetti G, Pichot M, Pickenpack M, Piergiovanni F, Pietka M, Pinard L, Pinto IM, Pitkin M, Pletsch HJ, Plissi MV, Poggiani R, Postiglione F, Prato M, Predoi V, Price LR, Prijatelj M, Principe M, Prix R, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Quetschke V, Raab FJ, Rabeling DS, Radke T, Radkins H, Raffai P, Rakhmanov M, Rankins B, Rapagnani P, Raymond V, Re V, Reed CM, Reed T, Regimbau T, Reid S, Reitze DH, Ricci F, Riesen R, Riles K, Roberts P, Robertson NA, Robinet F, Robinson C, Robinson EL, Rocchi A, Roddy S, Röver C, Rolland L, Rollins J, Romano JD, Romano R, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Sakata S, Sakosky M, Salemi F, Sammut L, de la Jordana LS, Sandberg V, Sannibale V, Santamaría L, Santostasi G, Saraf S, Sassolas B, Sathyaprakash BS, Sato S, Satterthwaite M, Saulson PR, Savage R, Schilling R, Schnabel R, Schofield RMS, Schulz B, Schutz BF, Schwinberg P, Scott J, Scott SM, Searle AC, Seifert F, Sellers D, Sengupta AS, Sentenac D, Sergeev A, Shaddock DA, Shapiro B, Shawhan P, Shoemaker DH, Sibley A, Siemens X, Sigg D, Singer A, Sintes AM, Skelton G, Slagmolen BJJ, Slutsky J, Smith JR, Smith MR, Smith ND, Somiya K, Sorazu B, Speirits FC, Sperandio L, Stein AJ, Stein LC, Steinlechner S, Steplewski S, Stochino A, Stone R, Strain KA, Strigin S, Stroeer AS, Sturani R, Stuver AL, Summerscales TZ, Sung M, Susmithan S, Sutton PJ, Swinkels B, Szokoly GP, Talukder D, Tanner DB, Tarabrin SP, Taylor JR, Taylor R, Thomas P, Thorne KA, Thorne KS, Thrane E, Thüring A, Titsler C, Tokmakov KV, Toncelli A, Tonelli M, Torre O, Torres C, Torrie CI, Tournefier E, Travasso F, Traylor G, Trias M, Trummer J, Tseng K, Turner L, Ugolini D, Urbanek K, Vahlbruch H, Vaishnav B, Vajente G, Vallisneri M, van den Brand JFJ, Van Den Broeck C, van der Putten S, van der Sluys MV, van Veggel AA, Vass S, Vaulin R, Vavoulidis M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Veltkamp C, Verkindt D, Vetrano F, Viceré A, Villar AE, Vinet JY, Vocca H, Vorvick C, Vyachanin SP, Waldman SJ, Wallace L, Wanner A, Ward RL, Was M, Wei P, Weinert M, Weinstein AJ, Weiss R, Wen L, Wen S, Wessels P, West M, Westphal T, Wette K, Whelan JT, Whitcomb SE, White D, Whiting BF, Wilkinson C, Willems PA, Williams L, Willke B, Winkelmann L, Winkler W, Wipf CC, Wiseman AG, Woan G, Wooley R, Worden J, Yakushin I, Yamamoto H, Yamamoto K, Yeaton-Massey D, Yoshida S, Yu P, Yvert M, Zanolin M, Zhang L, Zhang Z, Zhao C, Zotov N, Zucker ME, Zweizig J. Directional limits on persistent gravitational waves using LIGO S5 science data. PHYSICAL REVIEW LETTERS 2011; 107:271102. [PMID: 22243300 DOI: 10.1103/physrevlett.107.271102] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/09/2011] [Indexed: 05/31/2023]
Abstract
The gravitational-wave (GW) sky may include nearby pointlike sources as well as stochastic backgrounds. We perform two directional searches for persistent GWs using data from the LIGO S5 science run: one optimized for pointlike sources and one for arbitrary extended sources. Finding no evidence to support the detection of GWs, we present 90% confidence level (C.L.) upper-limit maps of GW strain power with typical values between 2-20×10(-50) strain(2) Hz(-1) and 5-35×10(-49) strain(2) Hz(-1) sr(-1) for pointlike and extended sources, respectively. The latter result is the first of its kind. We also set 90% C.L. limits on the narrow-band root-mean-square GW strain from interesting targets including Sco X-1, SN 1987A and the Galactic center as low as ≈7×10(-25) in the most sensitive frequency range near 160 Hz.
Collapse
|
70
|
Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Fu S, Piha-Paul SA, Naing A, Falchook GS, Janku F, Luthra R, Wen S, Kurzrock R. Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.cra2500] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA2500 Background: We initiated a personalized medicine program hypothesizing that tumor molecular analysis and use of targeted therapy to counteract the effects of specific aberrations would improve the outcomes of affected patients. Methods: Molecular analysis was performed in the M. D. Anderson CLIA-certified pathology laboratory. Patients whose tumors had an aberration were treated in the Phase I Program with a matched targeted agent, when available. Results: Tumor molecular analysis was feasible in 852 (89%) of 955 consecutive patients with advanced cancer. Of 852 patients (median, age 56 yrs; prior therapies 4), 354 (41.5%) had ≥ 1 aberration: 10% of patients had a PIK3CA mutation; 19% KRAS; 8% NRAS; 19% BRAF; 3% EGFR; and 2% had a CKIT mutation; 21% had PTEN loss. Results are shown in the table. Median time to treatment failure (TTF) in 161 patients with 1 aberration treated with matched targeted therapy was 5.3 months (95%CI: 4.1, 6.6) vs 3.2 months (95%CI: 2.9 – 4.0) for their prior systemic antitumor therapy (prior to referral to phase I) (p= .0003). For patients with 1 aberration, the CR+PR rate was 29% with matched targeted therapy vs. 8% without matching (p = .0001). The CR+PR rate was 6% in 438 patients without molecular testing treated on the same studies. Conclusions: Preliminary results suggest that in early clinical trials matching patients with targeted drugs based on their molecular profile results in (a) longer TTF compared to their prior therapy and (b) higher rates of response, survival and TTF compared to those seen in patients treated without molecular matching. Support: 3UL1 RR024148 04 S1 and IPCT. [Table: see text]
Collapse
|
71
|
El-Osta HE, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Kim KB, Wen S, Janku F, Kurzrock R. Clinical characterstics and outcomes of patients with BRAF-mutant advanced cancer in a phase I clinic: The University of Texas M. D. Anderson Cancer Center experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
72
|
Garrido-Laguna I, Kurzrock R, Wheler JJ, Falchook GS, Piha-Paul SA, Fu S, Naing A, Hinojosa C, Mistry R, Scamardo A, Culotta KS, Ekmekcioglu S, Wen S, Camacho LH, Ivy SP, Hong DS. Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3065] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
73
|
Iskander NG, Tsimberidou AM, Letourneau K, Wen S, Wheler JJ, Hong DS, Naing A, Kurzrock R. Phase I clinical trial outcomes in 93 patients with brain metastases: The M. D. Anderson Cancer Center experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e16546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
74
|
Choi W, Shah JB, Tran M, Svatek RS, Marquis L, Lee IC, Yu D, Adam L, Bondaruk JE, Wen S, Shen Y, Dinney CPN, Czerniak B, McConkey DJ, Siefker-Radtke AO. Use of P63 expression to define a lethal subset of muscle-invasive bladder cancers. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
75
|
Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Fu S, Piha-Paul SA, Naing A, Falchook GS, Janku F, Luthra R, Wen S, Kurzrock R. Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.cra2500] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|